Moderna stock price is skyrocketing on mRNA cancer vaccine trial news: Here’s what’s happening

Shares of the pharmaceutical company more than doubled on Wednesday after it announced, along with Merck, positive results from a Phase 3 trial.

[Photo: David L. Ryan/The Boston Globe via Getty Images]

Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck’s immunotherapy medication........

© Fast Company